Table 1 Comparison product type, applicant categorization, prevalence segmentation and consideration of significant benefit criterion for products that obtained OMP designations for rare neoplastic disorders and products that obtained OMP designation for other rare conditions

 Synthetic/extractive agent

53.5% (144)

53.8% (248)

 Biotechnology

46.5% (125)

46.2% (213)

 Academia/Public body

0% (0)^a

4% (20)^a

 Consulting

9% (25)

11% (52)

 Physical person

2% (6)^a

6% (27)^a

 SME

56% (150)^a

47% (216)^a

 Intermediate sized company

13% (35)

16% (75)

 Large Pharma

13% (35)^a

7% (31)^a

 Very large Pharma

7% (18)

9% (40)

  < 1/10,000

19% (51)

47.7%(220)

 1–3/10,000

69.1% (186)^a

41.4% (191)^a

  > 3/10,000

11.9% (32)^a

10.8% (50)^a

 Yes

75.1% (202)^a

44.3% (204)^a